- BNF:
- Skin
- Status:
- Red
- Decision Date:
- July 2018
Comments
RED: NICE TA521: for the treatment of moderate-to-severe plaque psoriasis in adults.
RED: NICE TA815 - Guselkumab for treating active psoriatic arthritis
after inadequate response to DMARDs (Decision date - September 2022)
CCG's are the responsible commissioners.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again
